CN104059126A - Antihypertensive peptide P16 as well as preparation method and application thereof - Google Patents
Antihypertensive peptide P16 as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN104059126A CN104059126A CN201410233895.3A CN201410233895A CN104059126A CN 104059126 A CN104059126 A CN 104059126A CN 201410233895 A CN201410233895 A CN 201410233895A CN 104059126 A CN104059126 A CN 104059126A
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- pressure lowering
- lowering peptide
- preparation
- enzymolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses an antihypertensive peptide P16 which has the amino acid sequence shown as SEQ IDNo.1. The antihypertensive peptide P16 is clear and definite in structure and good in antihypertensive activity. The invention further discloses a preparation method of the antihypertensive peptide P16. The preparation method has a compact process and realizes the standardization of the quality of the antihypertensive peptide P16. The invention further discloses an application of the antihypertensive peptide P16 in preparation of a medicine or a food with an antihypertensive function.
Description
Technical field
The invention belongs to polypeptide technical field, be specifically related to a kind of blood pressure lowering peptide P16 and its preparation method and application.
Background technology
Hypertension is a kind of common cardiovascular disorder, and not only morbidity is high for it, and often causes the other diseases such as the serious heart, brain, kidney, is the main Hazard Factor of cerebral apoplexy, coronary heart disease, heart failure and kidney disease.Blood pressure lowering peptide is the peptide material that a class has blood pressure lowering peptide effect, although from food proteins, obtain ace inhibitory peptide than the ACEI function of synthetic a little less than, but their importance is that the relatively weak material for lowering blood pressure of these activity is potential in the food of our daily absorption, and there is its unique advantage: the one, only can play hypotensive effect to hyperpietic, without hypotensive effect, thereby can not produce hypotensive excessive problem to normotensive; The 2nd, these peptides obtain under mild conditions through food-grade albumen enzyme, and its security is high, has no side effect; The 3rd, active diversity, except antihypertensive function, often simultaneously tool immunological enhancement, anticoagulation, absorption easy to digest, the function such as antitumor; The 4th, there is good acid, thermostability, water-soluble and vigorous degree with the feature such as change in concentration is blunt, thereby be easy to add in varieties of food items as functional factor.Be that raw material is prepared blood pressure lowering peptide with food, oneself starts agitation in food.
Chinese patent disclosed " a kind of preparation method of casein antihypertensive peptides " (application publication number CN102296100A), adopt stomach en-, trypsinase and Quimotrase substep casein hydrolysis, pass through the enzyme that goes out, after centrifugal, dry, obtain blood pressure lowering peptide first product, then obtain having ACE through macroporous absorption fat and dextran gel chromatography and suppress active casein antihypertensive peptides.But do not indicate specific blood pressure lowering peptide composition and structure, do not verify whether the product finally obtaining has hypotensive activity yet.
Chinese patent disclosed " preparation method of yak milk casein blood pressure lowering peptide " (application publication number CN102787155A), relate to a kind of yak milk casein that utilizes and prepare the method for blood pressure lowering peptide for raw material, mainly prepared ACE by techniques such as trypsin hydrolyzing, the enzyme that goes out, precipitation casein, ultrafiltration, pure filter, spraying are dry and suppressed active high blood pressure lowering peptide biased sample.But also the highest blood pressure lowering peptide composition of hypotensive activity is not carried out to Structural Identification, the quality product of can not standardizing.
Summary of the invention
The object of this invention is to provide a kind of blood pressure lowering peptide P16, this peptide structure is clear and definite, and hypotensive activity is good.
The present invention also aims to provide the preparation method of above-mentioned blood pressure lowering peptide P16, this preparation method's technique is succinct, the quality product of standardizing.
Last object of the present invention is to provide above-mentioned blood pressure lowering peptide P16 to have the application in medicine or the food of blood pressure reduction effect in preparation.
First object of the present invention is achieved by the following technical solution: a kind of blood pressure lowering peptide P16, its aminoacid sequence is as shown in SEQ IDNo.1.
Through qualification, the blood pressure lowering peptide P16 in the present invention, its aminoacid sequence is GPFPIIV (Gly-Pro-Phe-Pro-Ile-Ile-Val), specifically, as shown in SEQ IDNo.1, molecular weight is 741.2Da.
Second object of the present invention is achieved through the following technical solutions: the preparation method of above-mentioned blood pressure lowering peptide P16, contains following steps:
(1) get casein, after being dissolved in water, obtain the caseic aqueous solution;
(2) in the caseic aqueous solution, add trypsinase to carry out enzymolysis, tryptic add-on accounts for 0.1～0.2% of casein total mass, and hydrolysis temperature is 40～50 DEG C, enzymolysis time is 1～2h, pH value is 7.0～9.0, the enzyme processing of going out after enzymolysis, and enzyme liquid must go out;
(3) regulating pH value is that 4.0～5.0 not macromole of enzymolysis that make to go out in enzyme liquid carry out albumen precipitation, and removes the not high molecular weight protein of enzymolysis and precipitate, and must contain the clear liquid of blood pressure lowering peptide;
(4) adopt HPLC to carry out reverse phase silica gel purifying the clear liquid that contains blood pressure lowering peptide, collect the elutriant containing target compound, by after elutriant concentrate drying, obtain blood pressure lowering peptide P16.
In above-mentioned preparation method:
The consumption of water described in step of the present invention (1) is preferably 4～6 times of casein total mass, and solvent temperature is preferably 40～60 DEG C.
Temperature when go out enzyme in step of the present invention (2) is preferably 80～90 DEG C, and the enzyme time of going out is preferably 20～30min.
For the ease of some high molecular weight protein precipitation of enzymolysis not, in step of the present invention (3), first regulating pH value is 4.0～5.0, adopt filtration or centrifugation to remove the not macro-molecular protein precipitation of enzymolysis, when centrifugal, centrifuge speed is 3000～5000r/min, and centrifugation time is 20～30min.
In step of the present invention (4), HPLC adopts LC-8A Shimadzu high performance liquid chromatograph, chromatographic column is HW-0121, chromatographic condition is: flow velocity: 8mL/min, detects wavelength: 214nm, sample size: 2mL, moving phase: A pump ultrapure water, the TFA that is 0.1% containing volumn concentration, B pump acetonitrile, B pump starting point concentration is 25%, type of elution, binary gradient elution, gradient: 0.01～60min, 25～36%, 60.01min～80min, 36%, 80.01～90min, 90%～90%, 90.01～100min, 90%～25%.
The preparation method of blood pressure lowering peptide provided by the invention, mainly comprises and utilizes trypsin hydrolyzing casein, through regulating pH value, deproteinated, reverse phase silica gel purifying, the technique such as dry, prepares blood pressure lowering peptide monomer.
Last object of the present invention is achieved by the following technical solution: above-mentioned blood pressure lowering peptide P16 has the application in medicine or the food of blood pressure reduction effect in preparation.
Compared with prior art, tool of the present invention has the following advantages:
(1) the blood pressure lowering peptide P16 structure in the present invention is clear and definite, and its aminoacid sequence is GPFPIIV (Gly-Pro-Phe-Pro-Ile-Ile-Val), and molecular weight is 741.2Da;
(2) the blood pressure lowering peptide P16 blood pressure lowering effect in the present invention is good, in the time that concentration is 1mg/mL, can be up to 53.6% to the inhibiting rate of ACE enzyme, the ethanolic soln clear of good fluidity, 20% (quality percentage composition) blood pressure lowering peptide, color is pure white powder, that is to say the blood pressure lowering peptide in the present invention, the activity that can effectively suppress ACE enzyme, has huge practical value and economic benefit.
Brief description of the drawings
Fig. 1 is the HPLC collection of illustrative plates of liquid phase separation blood pressure lowering peptide P16 in the embodiment of the present invention 1;
Fig. 2 is the high-efficient liquid phase chromatogram of blood pressure lowering peptide P16 monomer in the embodiment of the present invention 1;
Fig. 3 is the mass spectrum of blood pressure lowering peptide P16 in the embodiment of the present invention 1.
Embodiment
Below in conjunction with drawings and Examples, the present invention will be further described, but do not limit in any form the present invention.
Embodiment 1
The blood pressure lowering peptide P16 that the present embodiment provides, its aminoacid sequence is as shown in SEQ IDNo.1.
Above-mentioned blood pressure lowering peptide P16 prepares by the following method:
(1) in beaker, add pure water 4000mL, open and stir 200rpm, in beaker, slowly drop into casein (permanent whole food level import casein, only for enumerating, be not limited in this) 1kg, stirring and dissolving under 40 DEG C of conditions, obtains the caseic aqueous solution;
(2) in the caseic aqueous solution, add trypsinase to carry out enzymolysis, enzymatic hydrolysis condition is: enzyme concentration is 0.1% of casein total mass, 40 DEG C of temperature of reaction, reaction times 1h, pH7.0;
(3) temperature is adjusted to 80 DEG C, insulation 30min, carries out sterilizing;
(4) adjust pH 4.0, the centrifugal 30min of 3000r/min, removes the not high molecular weight protein precipitation of enzymolysis, must contain the clear liquid of high reactivity blood pressure lowering peptide;
(5) reverse phase silica gel purifying, carries out reverse phase silica gel purifying by the clear liquid that contains high reactivity blood pressure lowering peptide, HPLC system: LC-8A Shimadzu preparative high-performance liquid chromatographic instrument again; Chromatographic column: HW-0121; Chromatographic condition: flow velocity: 8mL/min; Detect wavelength: 214nm; Sample size: 2mL; Moving phase: A pump ultrapure water (containing 0.1% (v/v) TFA, trifluoroacetic acid), B pump acetonitrile, B pump starting point concentration is 25%; Type of elution: binary gradient elution; Gradient: 0.01min～60min, 25%～36%; 60.01min～80min, 36%; 80.01min～90min, 90%～90%; 90.01min～100min, 90%～25%, repeat sample introduction, collecting high-activity blood pressure lowering peptide elutriant, the retention time of the unimodal chromatograms of this blood pressure lowering peptide is as shown in Fig. 1-2;
(6) by after centrifugal high reactivity blood pressure lowering peptide elutriant, collect supernatant liquor, vacuum concentration, lyophilize, obtains blood pressure lowering peptide monomer P16;
(7) qualification of blood pressure lowering peptide
Measure P16 molecular weight according to the LC-MS in Fig. 3, do Edman degraded to Research Centre for Proteome Analysis(Shanghai) again, measure P16 primary structure, known with caseic amino acid arrangement comparison again, the aminoacid sequence of the blood pressure lowering peptide obtaining in the present invention is GPFPIIV (Gly-Pro-Phe-Pro-Ile-Ile-Val), concrete as shown in SEQ IDNo.1.
(8) ACE (angiotensin-converting enzyme) suppresses determination of activity: urobenzoic acid method
A) preparation of reaction solution
In sample hose, add ACE solution that 10 μ L concentration are 0.2U/mL and the sample solution of 10 μ L, at 37 DEG C, be incubated 5min, add the HHL that 50 μ L concentration are 6.5mmolL-1 (purchased from SIGMA company of the U.S.) solution, after mixing, at 37 DEG C, be incubated 60min, add the hydrochloric acid soln that 85 μ L concentration are 1.0moL/L again and leave standstill 5min termination reaction, concrete operation step is as shown in table 1.
Table 1ACE suppresses active urobenzoic acid detection method reaction solution preparation process
B) chromatographic condition
1. chromatographic column: (200mm × 4.6mm, 5 μ m) for Diamonsil C18
2. moving phase and chromatographic condition: acetonitrile: ultrapure water=25:75 (containing 0.1% (v/v) TFA), flow velocity: 1mL/min; Detect wavelength: 228nm; Sample size: 20 μ L.
C) result is calculated
In formula:
The inhibiting rate (%) of R:ACEI sample to ACE,
A: the peak area of urobenzoic acid in control tube,
B: the peak area of urobenzoic acid in sample hose,
A
0: the peak area of urobenzoic acid in blank tube.
Under these conditions, obtain containing P16 blood pressure lowering peptide 0.38g, be 52.3% to the inhibiting rate of ACE enzyme, the molecular weight of blood pressure lowering peptide is 741.2Da, in ethanol, solvability is good, solubleness in ethanol is greater than 20%, is conducive to absorption of human body, can be used for preparing medicine or the food with blood pressure reduction effect.
Embodiment 2
The blood pressure lowering peptide P16 that the present embodiment provides, its aminoacid sequence is as shown in SEQ IDNo.1.
Above-mentioned high purity blood pressure lowering peptide P16 prepares by the following method:
(1) in beaker, add pure water 600mL, open and stir 200rpm, in beaker, slowly drop into casein 100g, stirring and dissolving under 50 DEG C of conditions;
(2) add trypsinase to carry out enzymolysis, enzymatic hydrolysis condition is: enzyme concentration is 0.2% of casein quality, 50 DEG C of temperature of reaction, reaction times 2h, pH9.0;
(3) temperature is adjusted to 90 DEG C, insulation 20min, enzyme goes out;
(4) adjust pH 5.0, the centrifugal 20min of 5000r/min, removes the not high molecular weight protein precipitation of enzymolysis;
(5) reverse phase silica gel purifying, elutriant carries out reverse phase silica gel purifying again, HPLC system: LC-8A Shimadzu preparative high-performance liquid chromatographic instrument; Chromatographic column: HW-0121; Chromatographic condition: flow velocity: 8mL/min; Detect wavelength: 214nm; Sample size: 2mL; Moving phase: A pump ultrapure water (containing 0.1% (v/v) TFA), B pump acetonitrile, B pump starting point concentration is 25%; Type of elution: binary gradient elution; Gradient: 0.01min～60min, 25%～36%; 60.01min～80min, 36%; 80.01min～90min, 90%～90%; 90.01min～100min, 90%～25%.Repeat sample introduction, collect P16 elution peak, collection process is with embodiment 1;
(6) by after centrifugal high reactivity blood pressure lowering peptide elutriant, collect supernatant liquor, vacuum concentration, lyophilize, obtains blood pressure lowering peptide monomer P16;
(7) qualification of blood pressure lowering peptide
Measure P16 molecular weight according to the LC-MS in Fig. 3, do Edman degraded to Research Centre for Proteome Analysis(Shanghai) again, measure P16 primary structure, known with caseic amino acid arrangement comparison again, the aminoacid sequence of the blood pressure lowering peptide obtaining in the present invention is GPFPIIV (Gly-Pro-Phe-Pro-Ile-Ile-Val), concrete as shown in SEQ IDNo.1.
(8) ACE (angiotensin-converting enzyme) suppresses determination of activity: urobenzoic acid method, and specifically mensuration process is continued to use the detection method in embodiment 1;
Under these conditions, obtain blood pressure lowering peptide P160.27g, molecular weight is 741.2Da, in the time that concentration is 1mg/mL, be that 53.6%, P16 blood pressure lowering peptide monomer solvability in ethanol is good to the inhibiting rate of ACE enzyme, can be used for preparing medicine or the food with blood pressure reduction effect.
Embodiment 3
The blood pressure lowering peptide P16 that the present embodiment provides, its aminoacid sequence is as shown in SEQ IDNo.1.
Above-mentioned high purity blood pressure lowering peptide P16 prepares by the following method:
(1) get casein, after being dissolved in water, obtain the caseic aqueous solution, wherein the consumption of water is 5 times of casein total mass, and solvent temperature is 50 DEG C;
(2) in the caseic aqueous solution, add trypsinase to carry out enzymolysis, tryptic add-on accounts for 0.15% of casein total mass, hydrolysis temperature is 45 DEG C, enzymolysis time is 1.5h, pH value is 8.0, the enzyme processing of going out after enzymolysis, and the temperature while going out enzyme is 85 DEG C, enzyme time of going out is 25min, and enzyme liquid must go out;
(3) regulating pH value is that the 4.5 not macromole of enzymolysis that make to go out in enzyme liquid carry out albumen precipitation, adopts filter type to remove the not high molecular weight protein of enzymolysis and precipitates, and must contain the clear liquid of high reactivity blood pressure lowering peptide;
(4) adopt HPLC to carry out reverse phase silica gel purifying, HPLC system the clear liquid that contains high reactivity blood pressure lowering peptide: LC-8A Shimadzu preparative high-performance liquid chromatographic instrument; Chromatographic column: HW-0121; Chromatographic condition: flow velocity: 8mL/min; Detect wavelength: 214nm; Sample size: 2mL; Moving phase: A pump ultrapure water (containing 0.1% (v/v) TFA), B pump acetonitrile, B pump starting point concentration is 25%; Type of elution: binary gradient elution; Gradient: 0.01min～60min, 25%～36%; 60.01min～80min, 36%; 80.01min～90min, 90%～90%; 90.01min～100min, 90%～25%.Repeat sample introduction, collect P16 elution peak, collection process is with embodiment 1;
(5) by after centrifugal high reactivity blood pressure lowering peptide elutriant, collect supernatant liquor, vacuum concentration, lyophilize, obtains blood pressure lowering peptide monomer P16.
(6) qualification of blood pressure lowering peptide
Measure P16 molecular weight according to the LC-MS in Fig. 3, do Edman degraded to Research Centre for Proteome Analysis(Shanghai) again, measure P16 primary structure, known with caseic amino acid arrangement comparison again, the aminoacid sequence of the blood pressure lowering peptide obtaining in the present invention is GPFPIIV (Gly-Pro-Phe-Pro-Ile-Ile-Val), concrete as shown in SEQ IDNo.1.
(7) ACE (angiotensin-converting enzyme) suppresses determination of activity: urobenzoic acid method, and specifically mensuration process is continued to use the detection method in embodiment 1;
Under these conditions, the molecular weight that obtains blood pressure lowering peptide P16 is 741.2Da, in the time that concentration is 1mg/mL, is that 52.8%, P16 blood pressure lowering peptide monomer solvability in ethanol is good to the inhibiting rate of ACE enzyme, can be used for preparing medicine or the food with blood pressure reduction effect.
Above-described embodiment is preferably embodiment of the present invention; but embodiments of the present invention are not restricted to the described embodiments; other any do not deviate from change, the modification done under spirit of the present invention and principle, substitutes, combination, simplify; all should be equivalent substitute mode, be included in protection scope of the present invention.
Claims (8)
1. a blood pressure lowering peptide P16, is characterized in that: its aminoacid sequence is as shown in SEQ ID No.1.
2. the preparation method of blood pressure lowering peptide P16 claimed in claim 1, is characterized in that containing following steps:
(1) get casein, after being dissolved in water, obtain the caseic aqueous solution;
(2) in the caseic aqueous solution, add trypsinase to carry out enzymolysis, tryptic add-on accounts for 0.1～0.2% of casein total mass, and hydrolysis temperature is 40～50 DEG C, enzymolysis time is 1～2h, pH value is 7.0～9.0, the enzyme processing of going out after enzymolysis, and enzyme liquid must go out;
(3) regulating pH value is that 4.0～5.0 not macromole of enzymolysis that make to go out in enzyme liquid carry out albumen precipitation, and removes the not high molecular weight protein of enzymolysis and precipitate, and must contain the clear liquid of blood pressure lowering peptide;
(4) adopt HPLC to carry out reverse phase silica gel purifying the clear liquid that contains blood pressure lowering peptide, collect the elutriant containing target compound, by after elutriant concentrate drying, obtain blood pressure lowering peptide P16.
3. the preparation method of blood pressure lowering peptide P16 according to claim 2, is characterized in that: the consumption of water described in step (1) is 4～6 times of casein total mass, and solvent temperature is 40～60 DEG C.
4. the preparation method of blood pressure lowering peptide P16 according to claim 2, is characterized in that: the temperature while going out enzyme in step (2) is 80～90 DEG C, and the enzyme time of going out is 20～30min.
5. the preparation method of blood pressure lowering peptide P16 according to claim 2, it is characterized in that: in step (3), adopt filtration or centrifugation to remove the not macro-molecular protein precipitation of enzymolysis, when centrifugal, centrifuge speed is 3000～5000r/min, and centrifugation time is 20～30min.
6. the preparation method of blood pressure lowering peptide P16 according to claim 2, it is characterized in that: step (4) HPLC adopts LC-8A Shimadzu high performance liquid chromatograph, chromatographic column is HW-0121, chromatographic condition is: flow velocity: 8mL/min, detect wavelength: 214nm, sample size: 2mL, moving phase: A pump ultrapure water, the TFA that is 0.1% containing volumn concentration, B pump acetonitrile, B pump starting point concentration is 25%, type of elution, binary gradient elution, gradient: 0.01～60min, 25～36%, 60.01min～80min, 36%, 80.01～90min, 90%～90%, 90.01～100min, 90%～25%.
7. blood pressure lowering peptide P16 claimed in claim 1 has the application in the medicine of blood pressure reduction effect in preparation.
8. blood pressure lowering peptide P16 claimed in claim 1 has the application in the food of blood pressure reduction effect in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410233895.3A CN104059126A (en) | 2014-05-29 | 2014-05-29 | Antihypertensive peptide P16 as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410233895.3A CN104059126A (en) | 2014-05-29 | 2014-05-29 | Antihypertensive peptide P16 as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104059126A true CN104059126A (en) | 2014-09-24 |
Family
ID=51547084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410233895.3A Pending CN104059126A (en) | 2014-05-29 | 2014-05-29 | Antihypertensive peptide P16 as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104059126A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085651A (en) * | 2015-09-02 | 2015-11-25 | 广州绿萃生物科技有限公司 | Casein phosphopeptide monomers and preparation method thereof |
| CN105859868A (en) * | 2016-06-08 | 2016-08-17 | 广西科技大学 | Angiotensin converting enzyme inhibition peptide and preparing method thereof |
| CN106046117A (en) * | 2016-07-04 | 2016-10-26 | 吉林农业大学 | Antihypertensive peptide and application thereof |
| CN114671939A (en) * | 2022-04-02 | 2022-06-28 | 华南理工大学 | ACE inhibitory peptide with mild, stable and long-acting antihypertensive effect and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007004876A2 (en) * | 2005-06-30 | 2007-01-11 | Campina Nederland Holding B.V. | Peptides inhibiting angiotensin-converting enzyme |
| CN102296100A (en) * | 2011-09-09 | 2011-12-28 | 江南大学 | Preparation method of casein antihypertensive peptides |
-
2014
- 2014-05-29 CN CN201410233895.3A patent/CN104059126A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007004876A2 (en) * | 2005-06-30 | 2007-01-11 | Campina Nederland Holding B.V. | Peptides inhibiting angiotensin-converting enzyme |
| US20100056458A1 (en) * | 2005-06-30 | 2010-03-04 | Campina Nederland Holding B.V. | Peptides Inhibiting Angiotensin-Converting Enzyme |
| CN102296100A (en) * | 2011-09-09 | 2011-12-28 | 江南大学 | Preparation method of casein antihypertensive peptides |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105085651A (en) * | 2015-09-02 | 2015-11-25 | 广州绿萃生物科技有限公司 | Casein phosphopeptide monomers and preparation method thereof |
| CN105085651B (en) * | 2015-09-02 | 2018-12-28 | 广州绿萃生物科技有限公司 | A kind of casein phosphopeptide monomer and preparation method thereof |
| CN105859868A (en) * | 2016-06-08 | 2016-08-17 | 广西科技大学 | Angiotensin converting enzyme inhibition peptide and preparing method thereof |
| CN106046117A (en) * | 2016-07-04 | 2016-10-26 | 吉林农业大学 | Antihypertensive peptide and application thereof |
| CN106046117B (en) * | 2016-07-04 | 2019-04-16 | 吉林农业大学 | A kind of blood pressure lowering peptide and its application |
| CN114671939A (en) * | 2022-04-02 | 2022-06-28 | 华南理工大学 | ACE inhibitory peptide with mild, stable and long-acting antihypertensive effect and application thereof |
| CN114671939B (en) * | 2022-04-02 | 2023-09-26 | 华南理工大学 | ACE (angiotensin converting enzyme) inhibitory peptide with mild blood pressure lowering effect, stable effect and long acting and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106831596B (en) | A method of preparing erythrothioneine | |
| CN103980347B (en) | Antihypertensive peptide of swim bladder of large yellow croaker and preparation method and use thereof | |
| CN105111282B (en) | A kind of walnut peptide with ACE inhibitory activity and preparation method thereof | |
| CN103242430B (en) | Angiotensin-converting enzyme inhibitory peptide, and preparation method and application thereof | |
| CN103992387B (en) | A kind of mussel boiling liquid bioactive peptide and its preparation method and application | |
| CN104059126A (en) | Antihypertensive peptide P16 as well as preparation method and application thereof | |
| CN103923177B (en) | A kind of inhibiting peptide of tonin of marine microalgae source | |
| CN103122022A (en) | Angiotensin converting enzyme inhibitory peptide derived from bitter almond protein and preparation method thereof | |
| CN104059127A (en) | Natural high-activity antihypertensive peptide, and preparation method and application thereof | |
| CN103204904B (en) | Dasyatis akajei chondroprotein polypeptide capable of resisting prostate cancer, and preparation method and application thereof | |
| CN102286590A (en) | Preparation method for jelly fish neurotensin | |
| CN104131055B (en) | Preparation method for phycoerythrin ACE inhibitory peptide | |
| CN103290086A (en) | A mung bean protein peptide having ACE inhibitory activity and a preparation method and applications thereof | |
| CN101455287A (en) | Melittin purification method | |
| CN106008669B (en) | A kind of hazelnut ace inhibitory peptide and preparation method thereof | |
| CN109957045A (en) | A kind of joint production process extracting heparin sodium and protein peptides from animal's liver | |
| CN105085651B (en) | A kind of casein phosphopeptide monomer and preparation method thereof | |
| CN104610446A (en) | Jerk filefish skin collagen antioxidative peptide and preparation method thereof | |
| CN107574214A (en) | A kind of preparation method of the whey protein peptide of anti-aging | |
| CN102199192A (en) | Method for separating functional polypeptide from tortoise-shell glue | |
| CN105803024B (en) | A method of ace inhibitory peptide is prepared using coconut cake globulin as raw material | |
| CN110183550A (en) | A kind of preparation process of refined heparin sodium | |
| CN109734822A (en) | A kind of comprehensive method for extracting abalone internal organs bioactive substance | |
| CN1587275A (en) | Separating and purifying technology for micro algae phycoerythrin | |
| CN101736051A (en) | Method for preparing mercenaria mercenaria linnaeus polysaccharide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140924 |
|
| RJ01 | Rejection of invention patent application after publication |